Abstract:A three-phase computational protocol for drug discovery has been developed that includes 1) 3D shape characterization of binding sites of a protein to predict optimum performance with selected molecular docking programs; 2) Implementation of predictive algorithms for pharmacokinetic properties and ADME profiling for targeted searches in the ZINC15 database; 3) Flexible molecular docking/dynamics protocols of small molecule/protein complexes for drug discovery. Focusing on cancer immunotherapy to implement this computational approach, the allosteric site of ecto-5’-nucleotidase (CD73), a regulator of the extracellular concentration of adenosine, is targeted for large scale small molecule searches. CD73 which hydrolyzes AMP to adenosine, is a GPI-anchored cell surface protein cleaved and activated in the extracellular environment as a homodimer. CD73 exhibits higher expression on lymphocytes, endothelial, and epithelial cells during a stress response and his been reported activated for various types of cancer. CD73 participates in blocking antitumor responses and enhances tumor growth and metastasis by producing high levels of adenosine in the extracellular environment. Protein coordinates of CD73 were downloaded for these from Rutgers Consortium of Structural Biology (RCSB) Protein Data Bank (PDB) and the potential inhibitory molecules from the ZINC15 Database. AutoDock Vina was selected as the ideal docking program for the target based on comparing predicting binding constants with actual Ki's and RMSD analysis of the co-crystallized ligand with the re-docked ligand. Once molecules with high affinity predicted scores were identified from docking, molecular dynamics studies were performed on the highest scoring protein/small molecule complexes. Studies were carried out using GROMACS, implemented with AMBER force field. Dissociation constants (Ki's) for the protein-ligand complex were calculated throughout MD runs. Conformational changes in the binding sites were observed visually and quantitified with PCA analysis. Novel hydrogen bonding networks and hydrophobic networks of residues in the 3D structures were identified to connect the active sites to the allosteric binding site using a MD protocol.

Identification Of Allosteric Inhibitors Of Cd73 Using Three-Phrase Computational Protocol For Drug Discovery

A Computational Approach to Identify Small Molecules Interact with Crystal Structure of Programmed Cell Death Protein 1 as Potential Therapeutics for Cancer Immunotherapy

Identification of Novel PI3Kδ Inhibitors by Docking, ADMET Prediction and Molecular Dynamics Simulations.

Computational Tools for Allosteric Drug Discovery: Site Identification and Focus Library Design

Computational workflow for discovering small molecular binders for shallow binding sites by integrating molecular dynamics simulation, pharmacophore modeling, and machine learning: STAT3 as case study

Identification of Phosphoinositide-3 Kinases Delta and Gamma Dual Inhibitors Based on the P110δ/γ Crystal Structure

Docking and 3D-QSAR Studies on the Imidazo[1,5-c]pyrimidine Derivative as EED Inhibitors

Biochemical and cellular monitoring of the activity of the ecto‐5′‐nucleotidase (CD73), a key cancer modulator using HTS‐formatted Bioluminescent Technology

Rational Design and Identification of Small-Molecule Allosteric Inhibitors of CD38

Turning down PI3K/AKT/mTOR signalling pathway by natural products: an in silico multi-target approach

Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.

Discovery of new STAT3 inhibitors as anticancer agents using ligand-receptor contact fingerprints and docking-augmented machine learning

Identification of Phelligridin-Based Compounds as Novel Human CD73 Inhibitors

Molecular Mechanism Concerning Conformational Changes of CDK2 Mediated by Binding of Inhibitors Using Molecular Dynamics Simulations and Principal Component Analysis

Structure-based drug design and molecular dynamics studies of an allosteric modulator targeting the protein–protein interaction site of PDK1

Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis

Computational Study on Novel Natural Inhibitors Targeting Janus Kinase 3

Using 3D-QSAR and Molecular Docking Insight into Inhibitors Binding with Complex-Associated Kinases CDK8

Computational study of novel natural inhibitors targeting aminopeptidase N(CD13)

Identification of natural marine compounds as potential inhibitors of CDK2 using molecular docking and molecular dynamics simulation approach

Identification of natural product as selective PI3Kα inhibitor against NSCLC: multi-ligand pharmacophore modeling, molecular docking, ADME, DFT, and MD simulations